Anna Kamieniak

Anna Kamieniak

Auto-generated profile, based on publicly available information

Anna Kamieniak

Student Scientific Society of Clinical Genetics, Medical University of Lublin, 11 Radziwillowska Str., 20-080 Lublin, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMateusz Pakosiński
Mateusz Pakosiński
MŻMartyna Żyła
Martyna Żyła
AKAnna Kamieniak
Anna Kamieniak
NKNatalia Kluz
Natalia Kluz
PGPaulina Gil-Kulik
Paulina Gil-Kulik
Introduction: Vitamin D is involved in numerous processes and is obtained both exogenously and endogenously. Its active form is 1,25-dihydroxycholecalciferol, which exerts its biological effects via the vitamin D receptor (VDR). The main factors influencing VDR density are polymorphisms of the VDR gene, which may affect, e.g., gene mRNA stability and also VDR gene expression. There are four main polymorphic sites within the gene, BsmI, ApaI, FokI and TaqI, and two polymorphisms related to the gene promoter: GATA and Cdx2. One of the functions of vitamin D is to modulate the immune system. It affects T lymphocytes, B lymphocytes and dendritic cells. Currently, vitamin D deficiency is a common global problem that is associated with an increased risk of autoimmune diseases, including Hashimoto’s thyroiditis. Numerous studies have demonstrated an association between low vitamin D levels and elevated thyroid-stimulating hormone (TSH) levels, and have also proven the existence of a negative correlation between vitamin D levels andanti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-Tg) antibody titers. Review objectives and a concise summary of the methodology: The review aims to analyze studies examining the relationship between specific VDR polymorphisms, vitamin D levels, and the development of various diseases, with a particular emphasis on Hashimoto’s thyroiditis. This review is based on original and review articles written in English published between March 2018–November 2024 searched primarily in the PubMed, and additionally in Google Scholar databases. A narrative review of the literature was conducted. Conclusions: The presence of specific VDR polymorphisms influences the effectiveness of vitamin D supplementation, but the role of supplementation in the prevention of autoimmune diseases has not been definitively confirmed. To date, studies have primarily involved relatively small groups of patients with significant population heterogeneity, with case–control investigations being the most common. Therefore, further research on larger, more homogeneous groups is recommended to achieve more standardized results. Additionally, the influence of epigenetic factors modulating VDR activity and its interactions with the environmental factors is also important.

17 May 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
JOJoanna Olszak
Joanna Olszak
KZKarolina Zalewa
Karolina Zalewa
RBRafał Budzyński
Rafał Budzyński
AKAnna Kamieniak
Anna Kamieniak
NKNatalia Klepacz
Natalia Klepacz
MKMarta Kaus
Marta Kaus
Introduction and Purpose: Cerebral palsy (CP) is a complex motor and postural disorder resulting from damage to the developing brain. The causes of CP are diverse and can occur at various stages of a child’s life— prenatal, perinatal, and postnatal. The aim of this paper is to review the scientific literature on the causes of CP, with a particular focus on the mechanisms of brain damage at each stage. Material and methods: A comprehensive literaturere view was conducted using the PubMed database, focusing on articles published until the end of 2024. The search included the keywords:"cerebral palsy","etiology","brain damage"and "prevention" in various combinations. Relevant studies were selected based on criteria such as etiology of cerebral palsy. Results: Analysis of available studies indicates that prenatal causes predominantly include genetic abnormalities, intrauterine infections, and exposure to toxins. Perinatal causes involve asphyxia, mechanical trauma, and prematurity. In the postnatal period, infections of the nervous system, traumatic brain injuries, and perinatal complications play a significant role. These causes are often interdependent, highlighting the necessity of a comprehensive approach to CP risk analysis. Conclusion: Understanding the multifactorial etiology of CP is essential for developing effective prevention strategies. Further research into the mechanisms of brain damage may contribute to reducing the incidence of new cases and improving the quality of life for children with CP.

9 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
ŻKŻaneta Kania
Żaneta Kania
GKGabriela Kapłon
Gabriela Kapłon
KGKarolina Glajcar
Karolina Glajcar
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and constitutes a significant public health concern due to its rising incidence and the absence of curative therapies. This review synthesizes recent pharmacological progress in the treatment of AD, with particular emphasis on emerging therapeutic strategies and investigational drug classes. The analysis draws on clinical trial data, regulatory documents, and peer-reviewed literature published between 2017 and 2025, identified through major scientific databases including PubMed, Scopus, and ClinicalTrials.gov. The most promising advances are associated with monoclonal antibodies directed against amyloid-beta pathology, such as aducanumab, lecanemab, and donanemab, which show potential to modify disease progression but also raise concerns related to efficacy, safety, and regulatory approval. Additional innovative approaches, including tau-targeted therapies, gene editing technologies such as CRISPR-Cas9, and RNA interference (RNAi), present new therapeutic opportunities, though they remain limited by challenges such as amyloid-related imaging abnormalities (ARIA), restricted delivery across the blood–brain barrier, and uncertainties regarding long-term clinical outcomes. While currently available pharmacological options are insufficient to halt or reverse AD, recent advancements, particularly in antibody-based therapies, represent an important step toward a new therapeutic era. Nevertheless, cautious interpretation of preliminary findings and rigorous clinical validation remain essential before these strategies can be translated into widespread clinical practice.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
DGDominika Gieroba
Dominika Gieroba
AKAnna Kamieniak
Anna Kamieniak
WPWeronika Perczyńska
Weronika Perczyńska
GKGabriela Kapłon
Gabriela Kapłon
JSJulia Szczotka
Julia Szczotka
KGKarolina Glajcar
Karolina Glajcar
Research objectives: Irritable bowel syndrome (IBS) is a functional disorder of the gastrointestinal tract with a complex pathogenesis in which the brain-gut axis is disrupted. Due to the multifactorial basis of the disorder, it is very important to combine pharmacological and psychological treatment with dietary treatment to alleviate patients' symptoms. The purpose of this dissertation was to present the effectiveness of pharmacological, dietary, psychological and novel treatments currently at research level in patients with irritable bowel syndrome. Method: In order to evaluate the effectiveness of various therapies in IBS, a systematic review was conducted. It covers articles from years 2020 - 2024, that were published in PubMed, MDPI, and Sage Journals databases. Key Findings: The treatment of irritable bowel syndrome requires a combination of different therapies to achieve an effective therapeutic effect. There is no specific form of treatment to cure IBS. Conclusions: Currently it is only possible to alleviate the discomfort and improve the quality of life by combining the various methods available. The method that seems to be the most effective is a combination of pharmacological, dietary and psychological treatment. Pharmacological therapy makes it possible to alleviate pain, constipation or diarrhea. The introduction of the FODMAP diet eliminates factors that adversely affect the intestinal microbiota, and psychotherapy, combined with pharmacological treatment of depression and anxiety, alters thinking and synthesizes hormones that affect the gut-brain axis. Alternative treatments are currently being researched, but it will take time and further research before these methods can be incorporated into standard therapy.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MCMarianna Chmiel
Marianna Chmiel
ATArtur Tumiński
Artur Tumiński
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
DGDominika Gieroba
Dominika Gieroba
Introduction and objective: Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome that may follow viral infections. We present a case of a 12-month-old boy who developed disseminated intravascular coagulation (DIC) and fulfilled HLH diagnostic criteria following influenza A virus infection. Extensive diagnostics excluded a genetic cause. Treatment based on the HLH-2018 protocol led to full recovery. This case emphasizes the importance of considering HLH in infants with severe systemic inflammation and coagulopathy, even in the absence of EBV infection. Early recognition and appropriate therapy are essential to improve outcomes. Results. This case report describes a 12-month-old boy with haemophagocytic lymphohistiocytosis (HLH) and disseminated intravascular coagulation (DIC) following influenza A infection. Despite negative genetic testing, the patient met HLH diagnostic criteria. Treatment per HLH-2018 protocol was successful. The case underscores the importance of early recognition of HLH in viral infections beyond Epstein-Barr virus.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
GKGabriela Kapłon
Gabriela Kapłon
WPWeronika Perczyńska
Weronika Perczyńska
JSJulia Szczotka
Julia Szczotka
GSGabriela Szpila
Gabriela Szpila
RFRemigiusz Flakus
Remigiusz Flakus
MCMarianna Chmiel
Marianna Chmiel
Background: Hashimoto’s thyroiditis is one of the most common autoimmune diseases, with a noticeable increase in incidence observed in recent years. Despite its high prevalence, current treatment options remain limited and primarily focus on managing the consequences rather than addressing the underlying causes of the condition. Metformin, although primarily prescribed for diabetes, has demonstrated promising anti-inflammatory and immunoregulatory properties in several autoimmune disease models. Aim: This review aims to evaluate the potential role of metformin in the management of Hashimoto’s thyroiditis, with a particular focus on its effects on immune regulation and thyroid function. Methods: An electronic literature search was performed using PubMed, Cochrane Library, ScienceDirect and Evidence‑Based Medicine Reviews. Search terms included ‘Metformin’, ‘Hashimoto disease’, ‘Thyroiditis’, ‘Thyroid’, ‘autoimmune disease’ as keywords. Only articles in English were considered. Conclusions: Preliminary data suggest that metformin, through its anti-inflammatory properties and modulation of AMPK/mTOR pathways, may influence immune responses in Hashimoto’s thyroiditis. Despite promising preclinical findings, further clinical trials involving human participants are required to evaluate its therapeutic efficacy and safety in this context.